UNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL. June 6, 2018
|
|
- Bonnie Joleen Parks
- 5 years ago
- Views:
Transcription
1 UNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL June 6,
2 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Review patient heterogeneity and its connection to unmet needs Explore unmet needs within the CLL/SLL and FL treatment landscapes Discuss how targeted treatment options may address unmet needs and improve treatment outcomes 1 CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; FL, follicular lymphoma.
3 2 PATIENT HETEROGENEITY IN CLL/SLL
4 CLL/SLL REMAINS AN INCURABLE DISEASE, AND PATIENTS EVENTUALLY RELAPSE OR DEVELOP REFRACTORY DISEASE CLL/SLL The median age of diagnosis is 72 years old 1 10-year relative survival (the ratio of actual survival to expected survival) is 64.6% for those years old, which is when most patients are diagnosed with CLL/SLL 2 Therapies that provide durable remission and improve survival are still needed Gribben JG. Expert Rev Anticancer Ther. 2010;10(9): Pulte D et al. J Hematol Oncol. 2016;9(28):1-8. *10-year-period relative survival for patients with CLL/SLL. Mean survival±se. N=24,771. Relative survival was calculated as the ratio of actual survival to expected survival (based on age, sex, race, and calendar year) to minimize the effect of non-cll-related death. 2
5 CLL/SLL THE CLL/SLL PATIENT POPULATION IS EXTREMELY HETEROGENEOUS Variable mutation status, disease burden, comorbidities, and performance status all contribute to patient heterogeneity 1,2 This diversity complicates disease management and results in highly variable treatment responses 1,2 Patients with del(17p) respond poorly to front-line chemoimmunotherapy 6 Older patients may not benefit as much as younger patients from front-line chemoimmunotherapy due to comorbidities and reduced organ function (including renal insufficiency) 3,7 As a result, there is no uniform standard of care in CLL/SLL 1 This is particularly evident in the relapsed/refractory setting 8 IGHV, immunoglobulin heavy chain variable; Notch1, Notch homolog 1, translocation-associated (Drosophila); TP53, tumor protein p Riedell PA et al. Am J Hematol Oncol. 2016;12: Hallek M. Am J Hematol. 2017;92(9): Shanafelt T. Hematology. 2013;2013(1): Thurmes P et al. Leuk Lymphoma. 2008;49(1): Rossi D et al. Blood. 2013;121(8): Nabhan C, Raca G, Lynn Wang Y. JAMA Oncol. 2015;1(7): Pulte D et al. J Hematol Oncol. 2016;9(28): National Comprehensive Care Network. 2018:1-85.
6 CLL/SLL PATIENT HETEROGENEITY RESULTS IN AREAS OF SIGNIFICANT UNMET NEED Available treatments, such as chemoimmunotherapy, are recommended for a broad range of patients with less consideration towards their heterogeneity 1,2 Multiple factors must be addressed to match treatments best suited for patients with unique biological and clinical challenges 1,2 There remain further opportunities to define specific patient populations who will best benefit from specific treatments 5 1. Castellino A et al. Mediterr J Hematol Infect Dis. 2017;9(1): Shanafelt T et al. Hematology. 2013;2013(1): Pulte D et al. J Hematol Oncol. 2016;9(28): Rossi D et al. Blood. 2013;121(8):
7 CLL/SLL THE RAI STAGING SYSTEM CLASSIFIES TUMOR BURDEN Disease Burden The Rai staging system comprises stages 0 IV and classifies CLL/SLL according to tumor burden 1,2 Degree of tumor burden is based solely on a physical examination and blood parameters 2 RAI STAGING SYSTEM Rai Stage 0 Rai Stage I & II Rai Stage III & IV Lymphocytosis Lymphocytosis Enlarged lymph nodes Enlarged spleen Enlarged liver Lymphocytosis Disease-related anemia Enlarged lymph nodes Enlarged spleen Enlarged liver Thrombocytopenia 6 1. Hallek M et al. Am J Hematol. 2017;92(9): NCCN Guidelines Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2018;1-85.
8 TUMOR BURDEN AND ASSOCIATED RISK GROUP ARE STRONG INDICATORS OF PATIENT OUTCOMES CLL/SLL Disease Burden Degree of tumor burden and Rai stage correspond to risk categories 1 Rai stage 0: low risk Rai stages I II: intermediate risk Rai stages III IV: high risk At diagnosis, 58% of patients are low risk (Rai stage 0) but may progress to high risk over time 1,2 Risk group at diagnosis is directly related to overall survival time. High-risk patients have poor prognosis 1,3 Higher tumor burden is associated with increased risk of tumor lysis syndrome upon treatment with Bcl-2 inhibitors 4 Bcl-2, B-cell lymphoma NCCN Guidelines Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2018; Thurmes P et al. Leuk Lymphoma. 2008;49(1): Eichhorst B et al. Ann Onc. 2015;26(5): Roberts et al. N Engl J Med 2016;374:
9 CLL/SLL HIGH-RISK PATIENTS HAVE THE LOWEST OVERALL SURVIVAL, HIGHLIGHTING THE NEED FOR ADDITIONAL TREATMENT OPTIONS Disease Burden Overall survival (OS) differs depending on patient risk category and disease burden Median OS: 5 years for high risk 8 years for intermediate risk 10 years for low risk OS data emphasize the need for additional treatment options in all risk categories *OS stratifying patients by Rai risk scoring. N= Thurmes P et al. Leuk Lymphoma. 2008;49(1):49-56.
10 CLL/SLL PATIENT GENETIC PROFILES ARE VARIABLE AND INFLUENCE PROGNOSIS Genetic Alterations The CLL/SLL genome carries the potential for multiple mutations 1 Among the more common mutations, del(17p), TP53, and del(11q) are associated with poor prognosis 2 Patients with del(17p) showed the worst 10-year OS relative to the general population 2 Del13q and mutated IGHV are associated with an improved patient prognosis compared to other genetic alterations 2,3 *10-year-period relative OS for CLL/SLL patients stratified by genetic mutation. N= Gaidano G, Rossi D. Hematol Am Soc Hematol Educ Progr. 2017;2017(1): Rossi D et al. Blood. 2013;121(8): Nabhan C et al. JAMA Oncol. 2015;1(7):
11 CLL/SLL GENETIC ALTERATIONS CONTRIBUTE TO CHEMOIMMUNOTHERAPY RESISTANCE, WITH del(17p) SHOWING THE WORST PROGNOSIS Genetic Alterations Patients with a 17p deletion have 1,2 : Highest resistance to chemoimmunotherapy Rapid disease progression Lowest 15-year probability of survival Suboptimal outcomes are also observed in patients with 3 : ZAP70 expression SF3B1 mutations NOTCH1 mutations del(11q) Unmutated IGHV * OS, N= Dohner H et al. N Engl J Med. 2000;343(26): Marcus R et al. Blood. 2005;105(4): Gaidano G, Rossi D. Am Soc Hematol Educ Progr. 2017;2017(1):
12 CLL/SLL MULTIPLE COMORBID CONDITIONS ARE COMMON IN NEWLY DIAGNOSED PATIENTS AND INFLUENCE TREATMENT CHOICE Comorbidities Additional comorbidities associated with treatment choice: renal insufficiency, atrial fibrillation, and bleeding 1-4 BPH, benign prostate hyperplasia; CAD, coronary arterial disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; PVD, pulmonary vascular disease; TIA, transient ischemic attack Thurmes P et al. Leuk Lymphoma. 2009;49(1): Goede V et al. Haematologica. 2014;99(6): Kazianka et al. Leukemia. 2017;31, Thompson et al. British Journal of Haematology. 2016;175,
13 CLL/SLL THE SUCCESS OF CHEMOIMMUNOTHERAPY IS HINDERED BY UNADDRESSED COMORBIDITIES Comorbidities Chemoimmunotherapy treatment has limited success in elderly, comorbid CLL/SLL patients In patients with 2 comorbidities: Median OS was reduced by 18.5 months (20.5%) Median PFS was reduced by 10.5 months (33.3%) Disease progression is the primary cause of death in patients with at least 2 comorbidities *N=193. PFS, progression-free survival. 12 Goede V et al. Haematologica. 2014;99(6):
14 CLL/SLL PATIENTS WHO RECEIVE FRONT-LINE CHEMOIMMUNOTHERAPY (FCR) HAVE A GREATER RISK OF SECONDARY MALIGNANCIES After front-line chemoimmunotherapy, patients with CLL have 2.38 times higher risk of secondary cancer than the general population The risk of AML and MDS is higher after chemoimmunotherapy-based therapy (5.1% during follow-up period of 4.4 years) AML, acute myeloid leukemia; FCR, fludarabine, cyclophosphamide, and rituximab; MDS, myelodysplastic syndrome. 13 Benjamini O et al. Leuk Lymphoma. 2015;56(6):
15 14 HOW SHOULD HETEROGENEITY FACTORS IMPACT TREATMENT STRATEGY IN CLL/SLL?
16 CLL/SLL CATEGORIZING PATIENTS BY BIOMARKER STATUS MAY HELP INFORM PHYSICIANS ON APPROPRIATE TREATMENT OPTIONS Genetic Alterations CLL/SLL genetic alterations can serve as prognostic biomarkers 1 Del(17p) and TP53 mutation are considered the most important in predicting prognosis 2 In high-risk CLL patients who carry del(17p), agents targeting the B-cell receptor pathway have shown significant activity 2 Bcl-2 inhibitors are not approved outside of del(17p) patients 3 CLL patients with NOTCH1 mutation may not respond well to anti-cd20 based therapies 2 Research is ongoing to identify biomarkers of resistance/sensitivity 2 CD, cluster of differentiation; FISH, fluorescent in situ hybridization Gaidano G, Rossi D. Hematol Am Soc Hematol Educ Progr. 2017;2017(1): Nabhan C et al. JAMA Oncol. 2015;1(7): ; 3. VENCLEXTA Prescribing Information 2017.
17 CLL/SLL TREATMENT STRATEGY SHOULD BE BASED ON AGE, GENETIC ALTERATIONS, AND PATIENT COMORBIDITIES Patient genetic profiles, particularly Del(17p)/TP53, and comorbidities should directly impact treatment strategy 1,6 Disease State Del(17p) mutation determines sequence of first-line treatment 1 Chronic Lymphocytic Leukemia Del(17p)/TP53 mutation status + - First Line BTK inhibitors High-dose corticosteroid Anti-CD20 & anti-cd52 antibodies Unfit/Frail, Age 65 Patient Alkylating agent CIT Fit Patient Purine analog CIT Relapsed/Refractory BTK inhibitors PI3K inhibitors Bcl-2 inhibitors Thalidomide analog CIT Anti-CD20 antibodies Reduced dose CIT BTK inhibitors PI3K inhibitors Bcl-2 inhibitors Alternative CIT Mutations (BTK-C481S and PLCγ2) can drive resistance to BTK inhibitors 2 Discontinuation due to acquired mutations can cause rapid progression of disease 3 If this occurs, PI3K inhibitors or targeting other pathways may be suitable alternatives 1,4 Comorbid patients 65 years old and unfit/frail are suited for chemoimmunotherapy with alkylating agents instead of toxic purine analogs 5 BCR, B-cell receptor; BTK, Bruton s tyrosine kinase; CIT, chemoimmunotherapy; PI3K, phosphoinositide 3-kinase Wierda WG et al. J Natl Compr Canc Netw. 2017;15(3): Gaidano G, Rossi D. Hematol Am Soc Hematol Educ Progr. 2017;2017(1): Chiron D et al. Cancer Discov. 2014;4(9): Maddocks KJ et al. JAMA Oncol. 2015;1(1): Gribben JG. Expert Rev Anticancer Ther. 2010;10(9): National Comprehensive Cancer Network, Inc. CLL/SLL Guidelines, Version
18 CLL/SLL TARGETED THERAPIES CAN BE AN ALTERNATIVE FOR PATIENTS NOT IDEALLY SUITED FOR CHEMOIMMUNOTHERAPY Targeted therapies regulate key signaling pathways tied to growth and survival and may also target the tumor microenvironment Targeted therapies include BTK inhibitors, PI3K inhibitors, and Bcl-2 inhibitors Targeted therapies can achieve a durable remission for relapsed/refractory patients Targeted therapies are also effective in high-risk disease, can be used in a personalized medicine approach, and provide an alternative to treatments that are associated with secondary malignancies This approach provides a paradigm shift towards an all-inclusive therapy for patients regardless of fitness level, comorbidity status, and genetic profile 17 Frustaci AM et al. Expert Rev Hematol. 2016;9(7):
19 CLL/SLL WHEN BTK INHIBITORS BECOME INEFFECTIVE OR NOT TOLERATED, PI3K INHIBITORS PROVIDE A VIABLE ALTERNATIVE Patients may experience intolerance or develop resistance to BTK inhibitors 1,2 In a retrospective analysis, 24% of patients discontinued treatment with a BTK inhibitor within 6.5 months, with toxicity being the most common reason for discontinuation 3 An oral PI3K inhibitor is a rational next step following an oral BTK inhibitor Mato AR et al. Haematologica. 2018;103: Frustaci AM et al. Expert Rev Hematol. 2016;9(7): Mato AR et al. Front-line ibrutinib therapy for chronic lymphocytic leukemia (CLL) in the real world: responses, toxicity, outcomes and subsequent therapies. Blood. 2017;130:3011.
20 19 PATIENT HETEROGENEITY IN FL
21 FL FL IS AN INCURABLE NHL, AND RELAPSE OCCURS FREQUENTLY AFTER FRONT-LINE THERAPY FL is the most common subtype of indolent NHL 1 35% of all NHL and 70% of indolent lymphomas The median age of diagnosis is 65 years old 2 FL remains incurable, even with an initial durable response to chemoimmunotherapy 3 Chronic nature of the disease highlights the continuous need for new therapies 5 High-risk patients, in particular, experience treatment failure and early POD with currently available therapies 6,7 NHL, Non-Hodgkin s lymphoma; POD, progression of disease Freedman A et al. Am J Hematol. 2015;90(12): Castellino A, Santambrogio E, Nicolosi M, et al. Follicular lymphoma: the management of elderly patient. Mediterr J Hematol Infect Dis. 2017; 9(1): Maddocks et al. J Natl Cancer Inst. 2017;109(3): Federico M et al. J Clin Oncol. 2013;31(12): Sorigue M et al. Expert Rev Hematol. 2017: Jurinovic V et al. Blood. 2016;128(8): Kahl BS et al. Blood. 2016;127(17):
22 FL PATIENTS WHO RELAPSE FOLLOWING FRONT-LINE CHEMOIMMUNOTHERAPY NEED ALTERNATIVE TREATMENT OPTIONS Despite treatment advances and a range of chemoimmunotherapy options, many FL patients experience frequent relapses and shorter remissions with front-line chemoimmunotherapy High rates of treatment failure with front-line chemoimmunotherapy demonstrate a need for alternative treatments High rates of 3-year treatment failure, up to 62%, occur with R-CVP, R-CHOP, and R-FM 3-year PFS rates: 52% (R-CVP), 63% (R-FM), and 68% (R-CHOP) Patients who relapse on front-line chemoimmunotherapy can develop secondary malignancies for a range of cancers, including colon, breast, prostate, lung, cervical, and uterine Patient risk level and disease characteristics play a role in treatment outcomes 21 R-CVP, rituximab plus cyclophosphamide, vincristine, prednisone; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone; R-FM, rituximab plus fludarabine and mitoxantrone. Federico M et al. J Clin Oncol. 2013;31(12):
23 FL THE PATIENT POPULATION IS HIGHLY HETEROGENEOUS, COMPLICATING DISEASE MANAGEMENT Variability in treatment success is due to heterogeneity of the disease state 1 Certain subgroups of patients are at higher risk of early progression of disease and relapse due to their clinical and molecular disease heterogeneity 1,2 Optimal sequence of therapy remains undefined as a result of patient heterogeneity 3 ARID1A, AT-rich interactive domain-containing protein 1A; CARD11, caspace recruitment domain-containing protein 11; CREBBP, CREB (camp response element-binding protein)-binding protein; ECOG, Eastern Cooperative Oncology Group; EP300, histone acetyltransferase p300; EZH2, enhancer of zeste homolog 2; FLIPI, Follicular Lymphoma International Prognostic Index; MEF2B, myocyte enhancer binding factor 2B Maddocks K et al. J Natl Cancer Inst. 2017;109(3): Kritharis A et al. Cancer Treat Res. 2015;165: Solal-Celigny P et al. Blood. 2004;104(5): Jurinovic V et al. Blood. 2016;128(6):
24 FL HETEROGENEITY INFLUENCES PATIENT PROGNOSIS The Follicular Lymphoma International Prognostic Index (FLIPI) is a clinical index to assess risk in patients with FL There remains an unmet need in all risk groups LDH, lactate dehydrogenase; ULN, upper limit of normal Solal-Celigny P et al. Blood. 2004;104: Kahl BS, Yang DT. Blood. 2016;127(17):
25 24 PATIENT HETEROGENEITY AND UNMET NEEDS IN FL
26 EARLIER PROGRESSION OF DISEASE (POD) DEFINES A HIGH-RISK PATIENT GROUP IN FL FL High-risk patients may experience disease progression within 24 months of diagnosis (POD 24) and initial chemoimmunotherapy 1 POD 24 is associated with poor outcomes and a higher chance of premature death 2 High-risk patients therefore present an unmet need in FL, where currently available treatment strategies are not effective Kahl BS, Yang DT. Blood. 2016;127(17): Sorigue M et al. Expert Rev Hematol. August 2017: Kridel R. et al. Blood. 2017;130(3)
27 FL POD 24 IS ALSO LINKED TO HISTOLOGICAL TRANSFORMATION Histological transformation is the changing of FL cells on multiple levels through 1 : Change in tumor grade Increased connections to the tumor microenvironment Greater number of genetic alterations Histological transformation is associated with shortened survival time 1 Approximately 30% of patients will transform to a more aggressive histology at some point in their disease 2 There are no treatment strategies that fully address the challenge of histological transformation Kridel R et al. Blood. 2017;130(3): Maddocks K et al. J Natl Cancer Inst. 2017;109(3):1-8.
28 FL ALTERNATIVE TREATMENT OPTIONS ARE NEEDED FOR PATIENTS WITH FOLLICULAR LYMPHOMA Disease State Follicular Lymphoma (Advanced stage, Grade 1-3) Symptoms Asymptomatic Symptomatic Tumor Burden Low High Low High First Line Watch and Wait* *Anti-CD20 antibodies *Patient Preference Anti-CD20 antibodies CIT Fit/young: Purine analog Unfit/elder: Alkylating Relapsed/Refractory PI3K inhibitors CIT Anti-CD20 antibodies Treatment in a relapsed/refractory setting is guided by success of early regimen, disease histology, and patient fitness 3 27 Kahl BS et al. Blood. 2016;127(17):
29 28 HOW SHOULD HETEROGENEITY FACTORS IMPACT TREATMENT STRATEGY IN FL?
30 FL TARGETED THERAPIES ARE A PROMISING STRATEGY FOR IMPROVED DISEASE CONTROL IN DIFFICULT-TO-TREAT PATIENTS Improved understanding of the biology of FL has led to increased use of novel targeted therapies Therapies that target the BCR pathway are rationally designed to induce a durable response for early-relapse patients independent of established risk factors 29 Maddocks K et al. J Natl Cancer Inst. 2017;109(3):1-8.
31 KEY TAKEAWAYS CLL/SLL and FL remain incurable, and current treatments only delay disease progression Available CLL/SLL and FL treatments do not adequately address all unmet needs of patients Optimal management of CLL/SLL and FL is complicated by the presence of heterogeneity-related factors, including disease burden, genetic alterations, and comorbidities Patients with CLL/SLL and FL may benefit from novel treatment strategies, such as targeted agents BTK inhibitors and Bcl-2 inhibitors have shown limited efficacy and are not approved for the treatment of FL 1,2 PI3K inhibitors are approved for FL in the relapsed/refractory setting IMBRUVICA Prescribing Information VENCLEXTA Prescribing Information ZYDELIG Prescribing Information 2018.
TREATMENT CONSIDERATIONS IN CLL/SLL AND FL. June 6, 2018
TREATMENT CONSIDERATIONS IN CLL/SLL AND FL June 6, 2018 0 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Discuss key considerations that influence patient outcomes Highlight the importance of patients quality
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationCLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic
CLL what do I need to know as an Internist in 218 Taimur Sher MD Associate Professor of Medicine Mayo Clinic Case 1 7 y/o white male for yearly medical evaluation Doing well and healthy Past medical history
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationManagement of Patients With Relapsed Chronic Lymphocytic Leukemia
Management of Patients With Relapsed Chronic Lymphocytic Leukemia Polina Shindiapina, MD, PhD, and Farrukh T. Awan, MD Abstract The management of chronic lymphocytic leukemia (CLL) has improved significantly
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationBendamustine for relapsed follicular lymphoma refractory to rituximab
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationRecent Advances in the Treatment of Non-Hodgkin s Lymphomas
671 Highlights of the NCCN 18th Annual Conference Recent Advances in the Treatment of Presented by Jeremy S. Abramson, MD, and Andrew D. Zelenetz, MD, PhD Abstract Non-Hodgkin s lymphomas (NHL) represent
More informationOutcomes of patients with CLL after discontinuing idelalisib
Outcomes of patients with CLL after discontinuing idelalisib Jacqueline C. Barrientos, Manmeen Kaur, Alexis Mark, Jaewon Chung, Nancy Driscoll, Alison Bender, Kanti R. Rai ASH Annual Meeting Abstracts
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Ibrutinib for treating chronic lymphocytic leukaemia.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Ibrutinib for treating chronic lymphocytic leukaemia Final scope Remit/appraisal objective To appraise the clinical and cost
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationREAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA.
REAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA Roberta Murru Struttura Complessa Ematologia e Centro Trapianti Presidio Ospedaliero
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationAktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation
Aktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation Dr. med. Petra Langerbeins Universitätsklinik Köln Deutsche CLL Studiengruppe (DCLLSG) OFFENLEGUNG
More informationLeukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington
Leukemia Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center University of Washington Discussed Abstracts Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody
More informationCLL: What s New from ASH
CLL: What s New from ASH John C. Byrd, MD D. Warren Brown Chair in Leukemia Research Professor of Medicine and Medicinal Chemistry Director, Division of Hematology The Ohio State University 2 Chronic Lymphocytic
More informationHow I treat High-risk follicular lymphoma
How I treat High-risk follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona 1) median OS raised from 10 to 18 y 2) advanced FL remains uncurable Stanford, n = 1334
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationMedication Policy Manual. Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru196 Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010 Committee Approval Date: January
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More informationInitial Diagnosis and Treatment 81 Male
Case SH2017-0359 Shiraz Fidai 1, Sandeep Gurbuxani 1, Girish Venkataraman 1, Gordana Raca 2, Madina Sukhanova 3, Michelle M Le Beau 3, Y. Lynn Wang 4, Mir Alikhan 4, Megan M.McNerney 4, Yuri Kobzev 4,
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationChronic Lymphocytic Leukaemia and Its Challenges for Insurers
Chronic Lymphocytic Leukaemia and Its Challenges for Insurers Sheetal Salgaonkar, M.D. Medical Director RGA Services India Private Limited Chronic lymphocytic leukaemia (CLL) is a slow-developing cancer
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationChronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia June, CLL survivor This publication was supported by Revised 2017 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia &
More informationLEUCEMIA LINFATICA CRONICA
LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction
More information1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 CHLORAMINOPHENE 2 mg, capsule B/30 (CIP code: 3369906) Applicant: TECHNI-PHARMA chlorambucil ATC code:
More informationGazyva (obinutuzumab)
Gazyva (obinutuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201807/01/2018 POLICY A. INDICATIONS The indications
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationManagement of CLL in the Targeted Therapy Era
Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More informationCLL treatment algorithm and state of the art
CLL treatment algorithm and state of the art Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CLL subgroups
More informationpan-canadian Oncology Drug Review Submitter or Manufacturer Feedback on a pcodr Expert Review Committee Initial Recommendation
pan-canadian Oncology Drug Review Submitter or Manufacturer Feedback on a pcodr Expert Review Committee Initial Recommendation Venetoclax (Venclexta) Chronic Lymphocytic Leukemia March 2, 2018 3 Feedback
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationIdelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities
Idelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities Benjamin L. Lampson, Tiago R. Matos, Siddha N. Kasar, Haesook Kim, Elizabeth A. Morgan, Laura
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationYounger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China
1266 Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China ZHENSHU XU, JINYAN ZHANG, SHUNQUAN WU, ZHIHONG ZHENG, ZHIZHE CHEN and RONG ZHAN
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationChronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances
Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances 2017 Master Class Course John C. Byrd, MD D Warren Brown Chair of Leukemia Research Distinguished University
More informationRole of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia: From Clinical Data to Individualized Care Ryan Jacobs, MD
Role of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia: From Clinical Data to Individualized Care Ryan Jacobs, MD Department of Hematology Levine Cancer Institute Carolinas Health
More informationWaldenstrom s Macroglobulinemia
Waldenstrom s Macroglobulinemia : Targeted Therapies/ Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called
More informationHow to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma
How to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma Peter A. Riedell, MD and Brad S. Kahl, MD Abstract Follicular lymphoma (FL) is the most common
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationChronic lymphocytic leukemia. E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015
Chronic lymphocytic leukemia E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015 Disclosures Travelling to ASH: Roche Consulting services: Janssen Questions in CLL: answers
More informationThe Clinical Characteristics and Treatment Response of Patients with Low Grade Non-Hodgkin Lymphoma
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (4), Page 789-796 The Clinical Characteristics and Treatment Response of Patients with Low Grade Non-Hodgkin Lymphoma Ahmed Yosry El-Agamawi,
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationSolomon Graf, MD February 22, 2013
Solomon Graf, MD February 22, 2013 Case Review of FL pathology, prognosis Grading of FL Grade 3 disease High proliferative index in grade 1/2 disease Pediatric FL Future of FL classification 57 yo man
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018
pan-canadian Oncology Drug Review Final Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationLEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA
CORSO TEORICO-PRATICO PER LA GESTIONE OTTIMALE DEI PAZIENTI AFFETTI DA LINFOMA MANTELLARE, LINFOMA FOLLICOLARE E LEUCEMIA LINFATICA CRONICA Torino, 21-23 Maggio 2018 LEUCEMIA LINFATICA CRONICA: TERAPIA
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationTargeted Oncology Chronic Lymphocytic Leukemia Virtual Tumor Board
Targeted Oncology Chronic Lymphocytic Leukemia Virtual Tumor Board Segment 1 Segment Title: Case 1: An Elderly Patient With Newly Diagnosed High-Risk CLL Segment Description: William Wierda, MD, PhD, and
More informationL approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro
L approccio terapeu-co Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro DISCLOSURE Nome: Maria Rosaria Cognome: Villa Impiego nell industria farmaceu7ca negli ul7mi 5 anni: NO Interssi
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationHeng Li, Wenjie Xiong, Huimin Liu, Shuhua Yi, Zhen Yu, Wei Liu, Rui Lyu, Tingyu Wang, Dehui Zou, Zengjun Li, Lugui Qiu
Original Article Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China Heng Li, Wenjie Xiong, Huimin
More informationCalquence. Calquence (acalabrutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.106 Subject: Calquence Page: 1 of 5 Last Review Date: March 16, 2018 Calquence Description Calquence
More informationCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL For reprint orders, please contact: reprints@futuremedicine.com The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/
More informationChronic Lymphocytic Leukemia: An Overview of Diagnosis, Prognosis, and Treatment
THE EMERGING ROLE OF TARGETED THERAPY FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PUBLISHING STAFF Managed Markets Jeff Prescott, PharmD Senior Clinical Project Manager Ida Delmendo Clinical Project
More informationPathology of the indolent B-cell lymphomas Elias Campo
Pathology of the indolent B-cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas Antigen selection NAIVE -B LYMPHOCYTE MEMORY B-CELL MCL FL LPL MZL CLL Small cell
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
well structured and organized, provided perc with a much deeper understanding of patients experiences with relapse or refractory CLL/SLL and its treatment. perc deliberated upon the cost effectiveness
More informationEmerging targeted therapies for follicular lymphoma A future without chemotherapy
Emerging targeted therapies for follicular lymphoma A future without chemotherapy Pier Luigi Zinzani Institute of Hematology L. e A. Seràgnoli University of Bologna FOLLICULAR LYMPHOMA: GENERAL ASPECTS
More informationWelcome & Introductions
Living with Chronic Lymphocytic Leukemia (CLL) Welcome & Introductions Dr. Brander s slides are available for download at www.lls.org/programs Wednesday, July 12, 2017 1 Living with Chronic Lymphocytic
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Idelalisib (Zydelig) for Chronic Lymphocytic Leukemia August 18, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Idelalisib (Zydelig) for Chronic Lymphocytic Leukemia August 18, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationIncidence-based Mortality Method to Partition Tumor-Specific Mortality Trends: Application to Non-Hodgkin Lymphoma Cancer
Incidence-based Mortality Method to Partition Tumor-Specific Mortality Trends: Application to Non-Hodgkin Lymphoma Cancer Nadia Howlader, Lindsay M Morton, Eric J Feuer, Caroline Besson, Eric A Engels
More informationManagement of 17p Deleted CLL Patients in the Era of Targeted Therapy
Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,
More information